Chemical Structures Technical Specifications BPC-157 Component Technical Specifications TB-500 Component The combinations structural diversity BPC-157s compact proline-rich sequence providing gastric acid resistance, paired with TB-500s larger actin-binding domain creates a multi-faceted approach to tissue repair that addresses both localized and systemic healing requirements
Welcome to Rocky Mountain Compounds Research Access Required Access to this website is restricted to qualified researchers and laboratories for laboratory and research use only
The committee members who voted yes generally believed the risks to be minimal, while those who voted no tended to worry about safety risks and effectiveness, and expressed concern that adding the peptide to the compounding list would create a false impression that it has been evaluated with the same rigorous standards as an FDA-approved drug
Veljaca, Marija et al, The development of PL 14736 for treatment of inflammatory bowel disease, Advanced in GI pharmacology, 2002 O-32
The diluent for any investigational peptide must always be the one specified in the trial protocol or product dossier
